Market revenue in 2023 | USD 4,741.1 million |
Market revenue in 2030 | USD 11,746.6 million |
Growth rate | 13.8% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Infectious Diseases |
Historical data covered | 2021 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Infectious Diseases |
Key market players worldwide | Moderna Inc, BioNTech SE ADR, CureVac NV Ordinary Shares, Arcturus Therapeutics Holdings Inc, Sanofi SA, GSK PLC, Pfizer Inc, AstraZeneca PLC, Argos Therapeutics, ETHRIS |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna therapeutics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the North America mrna therapeutics market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
The mRNA therapeutics market in North America is propelled by rapid regulatory approvals, exemplified by the swift clearance of COVID-19 vaccines like Pfizer-BioNTech and Moderna. Robust investments, particularly from initiatives such as Operation Warp Speed, are expected to fuel R&D. Future trends involve diversification into oncology and genetic disorders, with ongoing trials showcasing the potential of personalized cancer vaccines.
Advancements in lipid nanoparticle delivery systems and the customization of mRNA sequences underscore a shift toward precision medicine. Moderna, with substantial investments and ongoing clinical trials, exemplifies the region’s commitment to advancing mRNA technology for diverse therapeutic applications. Moreover, in March 2022, RNA immune, Inc., a biopharmaceutical firm specializing in mRNA-based therapeutics and vaccines, disclosed the successful closure of a Series A funding round, securing approximately USD 27 million.
The funding, led by existing shareholders Sirnaomics Ltd. & Smooth River Limited, and participation from a new investor managed by Rotating Boulder Fund, aimed to expedite the company’s R&D efforts. RNAimmune’s focus includes mRNA vaccines and drug discovery targeting infectious diseases, cancer, & rare diseases. This injection of capital reflects investor confidence and underscores the company’s commitment to advancing innovative solutions in mRNA therapeutics.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America mrna therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into North America mrna therapeutics market from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account